In this study, while the outcome obtained with the anti-PD-1 therapy was limited to a partial regression and correlated with an increased CD4+ Treg/CD4+ Th cells ratio, a complete tumor regression was achieved by the synergistic response when anti-PD-1 and anti-TGF-β antibodies were combined. This evidence concerns the gene PDCD1 and neoplasm.